It is a link for moving within the page.

  1. HOME
  2. About Otsuka
  3. News Releases
  4. News releases related to oncology

News ReleasesNews releases related to oncology

2021

2020

2019

2018

2017

2016

2015

2014

2013

2012

2011

2010

Pharmaceuticals
Starting co-promotion of the anti-cancer agent “SPRYCEL® Tablet 20mg and SPRYCEL® Tablet 50mg” (dasatinib) in Japan
Pharmaceuticals
The results of a subset analysis of Japanese patients from the DASISION trial comparing SPRYCEL® (dasatinib) with imatinib in the treatment of newly diagnosed Philadelphia chromosome positive chronic myelogenous leukemia.
Pharmaceuticals
Follow-Up Results from Study Comparing SPRYCEL® (dasatinib) to Imatinib in First-Line Treatment of Adults with Ph+ CP-CML Demonstrate Improved Response Rates Consistent with 12 Month Data*1
Pharmaceuticals
FDA Approves SPRYCEL® (dasatinib) as Treatment for Adult Patients with Newly Diagnosed Ph+ Chronic Myeloid Leukemia in Chronic Phase
Pharmaceuticals
OTSUKA OPENS FIRST OFFICE IN CANADA Important Milestone for Growing North American Pharmaceutical Operations
Pharmaceuticals
SPRYCEL® (dasatinib) Receives FDA Priority Review for the Treatment of Adult Patients with Newly Diagnosed Chronic Myeloid Leukemia (CML) in Chronic Phase
Pharmaceuticals
GW and Otsuka Agree Three Year Extension to Global Cannabinoid Research Collaboration
Pharmaceuticals
Four-Year Follow-Up Data for SPRYCEL® (dasatinib) Demonstrate 82 Percent Overall Survival in Patients with Chronic Myeloid Leukemia Who Failed Gleevec®*
Pharmaceuticals
SPRYCEL® (dasatinib) Demonstrates Superior Confirmed Complete Cytogenetic Response Rates Compared to Gleevec®* in Study of Adult Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase
Pharmaceuticals
Otsuka Pharmaceutical Co., Ltd. and Fuso Pharmaceutical Industries, Ltd. Conclude Agreement for the Manufacturing and Commercialization of Therapeutic Cancer Vaccine, OTS102

2009

2007